Lung Ultrasound Changes in Covid 19 Patients Discharged From Hospital

Sponsor
Chelsea and Westminster NHS Foundation Trust (Other)
Overall Status
Completed
CT.gov ID
NCT05062603
Collaborator
(none)
23
Enrollment
1
Location
4.8
Actual Duration (Months)
4.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Lung ultrasound has been used to help diagnose COVID-19 as an alternative to CT scanning and chest X-ray. CT scanning is onerous and there are difficulties taking critically unwell patients there as well as decontamination issues.

Chest X-ray misses up to 40% of COVID diagnoses. Although lung ultrasound can diagnose, the investigators do not know how long these lung ultrasound changes last. The investigators would like to follow up patients to characterise the pattern of changes and how long they last. This is particularly important given a potential second surge of COVID-19 is looming and the investigators would like to know if lung ultrasound changes are new or old in patients presenting during this second wave and in the future.

Condition or DiseaseIntervention/TreatmentPhase

    Detailed Description

    Ultrasound has been invaluable during this pandemic to diagnose COVID-19. The investigators have used it alongside CT scanning to rationalise the number of CT scans especially when patients are unstable. The investigators do not know how long these changes last on lung ultrasound after discharge and the investigators wish to study this.

    This is because patients will start presenting shortly who have a history of COVID-19 with acute medical problems and if the investigators are to use lung ultrasound again the investigators would like to know whether the changes the investigators see are new or old.

    This is vitally important before a second surge and especially so before winter. This may also facilitate triage of patients from the front door in the Emergency department to different areas (such as COVID-19 zones or clean areas).

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    23 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Prospective Observational Study Looking at Lung Ultrasound Changes During Recovery From COVID19 Infection
    Actual Study Start Date :
    Jul 9, 2020
    Actual Primary Completion Date :
    Dec 1, 2020
    Actual Study Completion Date :
    Dec 1, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Assessment of lung ultrasound changes over the time period of follow up. [Approximately 3 months or until the ultrasound changes in the lung had normalised]

      The assessment will determine how long it takes for lung ultrasound changes to resolve following discharge from hospital in patients who were diagnosed with COVID-19 (unit of measurement: days).

    Secondary Outcome Measures

    1. Exploration of ongoing symptoms [Approximately 3 months or until the ultrasound changes in the lung had normalised]

      Ongoing symptoms will be explored by using screening questions.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 18 years old or older

    • Confirmed COVID-19 positive with changes on CXR or CT scan

    • Having had an initial lung ultrasound in the Emergency department when they were first admitted into the hospital.

    Exclusion Criteria:
    • Pre-existing lung disease

    • Heart failure

    • Under 18 years old.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Chelsea and Westminster HospitalLondonGreater LondonUnited KingdomSW10 9NH

    Sponsors and Collaborators

    • Chelsea and Westminster NHS Foundation Trust

    Investigators

    • Principal Investigator: Paramjeet Deol, MBChB FRCEM, Chelsea and Westminster Hospital NHS Foundation Trust

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Chelsea and Westminster NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT05062603
    Other Study ID Numbers:
    • C&W20/036
    • IRAS number 286015
    First Posted:
    Sep 30, 2021
    Last Update Posted:
    Oct 8, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Chelsea and Westminster NHS Foundation Trust
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 8, 2021